Vassiliki A Papadimitrakopoulou

Vassiliki A Papadimitrakopoulou

UNVERIFIED PROFILE

Are you Vassiliki A Papadimitrakopoulou?   Register this Author

Register author
Vassiliki A Papadimitrakopoulou

Vassiliki A Papadimitrakopoulou

Publications by authors named "Vassiliki A Papadimitrakopoulou"

Are you Vassiliki A Papadimitrakopoulou?   Register this Author

64Publications

2031Reads

42Profile Views

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

J Clin Oncol 2018 09 30;36(26):2702-2709. Epub 2018 Jul 30.

Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Myung-Ju Ahn, Sungkyunkwan University School of Medicine; Hye Ryun Kim, Yonsei University College of Medicine, Seoul; Ji-Youn Han, National Cancer Center, Goyang, Republic of Korea; Marina Chiara Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Nobuyuki Katakami, Institute of Biomedical Research and Innovation, Kobe, Japan; Rachel Hodge, Paramjit Kaur, Andrew P. Brown, and Dana Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Vassiliki A. Papadimitrakopoulou, The University of Texas MD Anderson Cancer Center, Houston, TX; and Tony S.K. Mok, Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9363DOI Listing
September 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.

Radiol Clin North Am 2018 May;56(3):485-495

Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00338389183001
Publisher Site
http://dx.doi.org/10.1016/j.rcl.2018.01.012DOI Listing
May 2018

Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging.

J Thorac Imaging 2017 Sep;32(5):300-312

Departments of *Diagnostic Radiology ‡Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX †Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RTI.0000000000000291DOI Listing
September 2017

Targeted Therapy and Imaging Findings.

J Thorac Imaging 2017 Sep;32(5):313-322

Departments of *Diagnostic Radiology †Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RTI.0000000000000294DOI Listing
September 2017

Osimertinib in EGFR T790M-Positive Lung Cancer.

N Engl J Med 2017 05;376(20):1993-4

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1703339DOI Listing
May 2017

Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.

Clin Cancer Res 2017 Feb 7;23(3):618-622. Epub 2016 Nov 7.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2815DOI Listing
February 2017

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

N Engl J Med 2017 02 6;376(7):629-640. Epub 2016 Dec 6.

From the State Key Laboratory in Oncology in South China, Sir Y.K. Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong (T.S.M.), the Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), and the Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing (Y.H.) - all in China; the Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, (M.-J.A.), and the Yonsei Cancer Center, Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine (H.R.K.), Seoul, South Korea; the Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (M.C.G.); the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta (S.S.R.); the Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto (F.A.S.); the Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan (H.A.); the Department of Thoracic Oncology, the Netherlands Cancer Institute, Plesmanlaan, Amsterdam (W.S.M.E.T.); the Clinical Research Unit, Division of Cancer Services, St. George Hospital, Kogarah, NSW, Australia (C.K.L.); the Department of Hematology-Oncology, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany (M.S.); AstraZeneca, Cambridge, United Kingdom (A.T., H.M., M.M., S.G.); and the Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (V.A.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1612674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027PMC
February 2017

Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.

Clin Cancer Res 2016 Nov 8;22(21):5177-5182. Epub 2016 Sep 8.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1415DOI Listing
November 2016

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.

Lung Cancer 2016 09 21;99:79-87. Epub 2016 Jun 21.

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 W. Holcombe Blvd., Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.06.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991495PMC
September 2016

Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Clin Cancer Res 2016 07 5;22(14):3630-42. Epub 2016 Feb 5.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947453PMC
July 2016

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

Stat Biosci 2016 Jun 4;8(1):99-128. Epub 2014 Dec 4.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12561-014-9124-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014437PMC
June 2016

New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development.

Cancer Prev Res (Phila) 2015 Nov 4;8(11):1027-35. Epub 2015 Sep 4.

Cancer Research Center of Lyon, UMR INSERM 1052-CNRS 5286, Lyon, France. Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France. Department of Medicine, Centre Léon Bérard, Lyon, France. Université de Lyon, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-14-0179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777304PMC
November 2015

Lung-MAP--framework, overview, and design principles.

Chin Clin Oncol 2015 Sep;4(3):36

Department of Thoracic and Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.09.02DOI Listing
September 2015

Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.

Cancer Prev Res (Phila) 2013 May;6(5):375-8

Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-13-0114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683314PMC
May 2013

Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.

J Thorac Oncol 2012 Dec;7(16 Suppl 5):S379-82

Department of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31826df0f0DOI Listing
December 2012

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).

Invest New Drugs 2011 Jun 22;29(3):499-505. Epub 2010 Jan 22.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9380-zDOI Listing
June 2011

The future of NSCLC: molecular profiles guiding treatment decisions.

Oncology (Williston Park) 2011 Jun;25(7):607, 614

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
June 2011

Gene expression profiling predicts the development of oral cancer.

Cancer Prev Res (Phila) 2011 Feb;4(2):218-29

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-10-0155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074595PMC
February 2011

Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy.

Head Neck 2010 Apr;32(4):473-80

The University of Texas M. D. Anderson Cancer Center, Department of Radiation Oncology, Unit 97, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.21207DOI Listing
April 2010

Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.

Cancer Prev Res (Phila) 2009 Sep 8;2(9):823-9. Epub 2009 Sep 8.

Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-09-0077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910364PMC
September 2009

Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.

J Clin Oncol 2009 Feb 15;27(4):599-604. Epub 2008 Dec 15.

Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.17.1850DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645856PMC
February 2009

High-dose fenretinide in oral leukoplakia.

Cancer Prev Res (Phila) 2009 Jan;2(1):22-6

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-08-0100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161148PMC
January 2009

Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment.

Int J Radiat Oncol Biol Phys 2007 Jul;68(3):719-30

Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2007.01.032DOI Listing
July 2007

The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis.

Cancer Lett 2006 Jul 21;239(1):136-43. Epub 2005 Sep 21.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2005.08.009DOI Listing
July 2006

Akt activation correlates with adverse outcome in tongue cancer.

Cancer 2005 Dec;104(11):2430-6

Department of Head & Neck/Thoracic Medical Oncology, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.21476DOI Listing
December 2005

Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis.

Cancer 2005 Mar;103(5):952-9

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.20879
Publisher Site
http://dx.doi.org/10.1002/cncr.20879DOI Listing
March 2005

Focus on head and neck cancer.

Cancer Cell 2004 Apr;5(4):311-6

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
April 2004

Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.

Clin Cancer Res 2004 Mar;10(5):1565-73

Intervention Section, Cell and Cancer Biology Branch, Department of Pathology and Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1906, USA.

View Article

Download full-text PDF

Source
March 2004

Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.

Oncology (Williston Park) 2003 Jul;17(7 Suppl 7):17-21

Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
July 2003

Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer.

J Natl Cancer Inst 2003 Feb;95(3):198-205

Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/95.3.198DOI Listing
February 2003

Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions.

Cancer Epidemiol Biomarkers Prev 2002 Dec;11(12):1605-10

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
December 2002